56367-24-9

Basic information

• Product Name: 5-ISOPROPYL-1H-PYRAZOL-3-AMINE
• Synonyms: 3-Isopropyl-1H-pyrazol-5-ylaMine;1H-Pyrazol-3-aMine, 5-(1-Methylethyl)-;EOS-60939
• CAS NO: 56367-24-9
• Molecular Formula: C₆H₁₁N₃
• Molecular Weight: 125.17
• Mol File: 56367-24-9.mol
• Article Data: 16

Chemical Properties

• Boiling Point: 299.7°C at 760 mmHg
• Flash Point: 160.3°C
• Appearance: /
• Density: 1.104g/cm³
• Vapor Pressure: 0.00117mmHg at 25°C
• Refractive Index: 1.57
• PKA: 15.60±0.10(Predicted)
• CAS DataBase Reference: 5-ISOPROPYL-1H-PYRAZOL-3-AMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-ISOPROPYL-1H-PYRAZOL-3-AMINE(56367-24-9)
• EPA Substance Registry System: 5-ISOPROPYL-1H-PYRAZOL-3-AMINE(56367-24-9)

Safety Data

• Hazardous Substances Data: 56367-24-9(Hazardous Substances Data)

Usage

Uses

3-Isopropyl-1H-pyrazol-5-amine

InChI:InChI=1/C6H11N3/c1-4(2)5-3-6(7)9-8-5/h3-4H,1-2H3,(H3,7,8,9)

Upstream product

• 29509-06-6 4-methyl-3-oxopentanonitrile 
• 2861-04-3 4-methyl-2,3-pentadienenitrile 

Downstream Products

• 1616085-93-8 2-chloro-N-(5-isopropyl-1H-pyrazol-3-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-amine 
• 1574358-73-8 3-isopropyl-1-(3-(2-morpholinoethoxy)phenyl)-1H-pyrazol-5-amine 

Relevant articles and documents

Identification of TRD-35 as Potent and Selective DRAK2 Inhibitor

-

Synthesis of aminopyrazole analogs and their evaluation as CDK inhibitors for cancer therapy

We synthesized a library of aminopyrazole analogs to systematically explore the hydrophobic pocket adjacent to the hinge region and the solvent exposed region of cyclin dependent kinases. Structure-activity relationship studies identified an optimal substitution for the hydrophobic pocket and analog 24 as a potent and selective CDK2/5 inhibitor.

Pyrazolotriazines as inhibitors of nucleases

The invention provides compounds represented by the structural formula (1): wherein R1, R2, R3 and R4 are as defined in the claims. The compounds are inhibitors of nucleases, and are useful in particular in a method of treatment and/or prevention of proliferative diseases, neurodegenerative diseases, and other genomic instability associated diseases.